SCHEDULE: Camac Partners Discloses 6.8% Stake in Cryo-Cell

Camac Partners, LLC and affiliated entities have filed an amended Schedule 13D, disclosing beneficial ownership of approximately 6.8% of Cryo-Cell International Inc.'s common stock.

Summary

• Camac Partners, LLC, along with Camac Capital, LLC, Camac Fund, LP, and Eric Shahinian, have jointly filed an amendment to their Schedule 13D.
• The filing discloses beneficial ownership of 551,081 shares of common stock in CRYO CELL INTERNATIONAL INC.
• This represents approximately 6.8% of the issuer's outstanding common stock, based on 8,055,150 shares outstanding as of April 14, 2026.
• The aggregate purchase price for these shares was approximately $1,807,998, including brokerage commissions.
• The Reporting Persons acquired these securities believing they were undervalued and represented an attractive investment opportunity.
• They may seek to increase or decrease their position, enter into transactions to hedge economic exposure, and may engage in discussions with management and the Board regarding board composition, corporate governance, asset monetization, and return of capital.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, as it signals investor confidence and potential for strategic improvements, but lacks concrete operational or financial performance data.

Positives

• The Reporting Persons view the securities as an attractive investment opportunity due to perceived undervaluation.
• The acquisition of a significant stake (6.8%) indicates confidence in the company's potential.
• The intention to engage with management and the Board suggests a proactive approach to potentially improving shareholder value.

Negatives

• The filing does not contain specific financial performance data or operational updates, making it difficult to assess the company's current health beyond the investment thesis.
• The potential for future stock sales or hedging activities could create downward pressure on the stock price.

Risks

• Market conditions and the availability of other investment opportunities could influence the Reporting Persons' decision to increase or decrease their stake.
• Discussions with management and the Board regarding corporate governance and asset monetization could lead to strategic shifts that may not align with all shareholder interests.
• The Reporting Persons reserve the right to change their plans or intentions regarding their investment at any time.

Future Outlook

The Reporting Persons may endeavor to increase or decrease their position in the Issuer, enter into transactions to hedge their economic exposure, and may engage in communications with management and the Board regarding various strategic aspects including board composition, corporate governance, asset monetization, and return of capital. Their future actions will depend on market conditions, other investment opportunities, and the desirability of the Issuer's stock prices.

Management Comments

• The Reporting Persons purchased the securities of the Issuer reported herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity.
• The Reporting Persons intend to review their investments in the Issuer on a periodic basis and may from time to time engage in communications and discussions with management and the Board of Directors of the Issuer (the "Board"), other stockholders of the Issuer and third parties concerning, among other things, Board composition and corporate governance, levels of expenditures, monetization of all of the company's assets, and return of capital to shareholders.
• The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.

Industry Context

StockSavvy.ai notes that this Schedule 13D filing indicates an activist investor's interest in Cryo-Cell International Inc. Such filings often precede engagement with management or strategic proposals aimed at enhancing shareholder value, which is a common trend in the biotechnology and healthcare sectors where companies may be undervalued or have underutilized assets.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through strategic engagement, but also potential volatility if activist actions lead to significant company changes or if the activist sells shares.
• Management and Board: Will likely face engagement from the Reporting Persons regarding strategic direction, asset monetization, and corporate governance.
• Employees: Potential impact on job security or company strategy depending on the outcomes of discussions with management.
• Creditors: Indirect impact through potential changes in company strategy or financial performance.

Next Steps

• Reporting Persons may increase or decrease their position in the Issuer.
• Reporting Persons may enter into transactions to hedge their economic exposure.
• Reporting Persons may engage in communications and discussions with management and the Board regarding various strategic matters.

Key Dates

Recommendation

The filing indicates a significant stake by an investor who believes the stock is undervalued and intends to engage with management. While this suggests potential upside, the lack of specific operational details or immediate strategic plans warrants a 'hold' recommendation until further clarity emerges on the activist's objectives and the company's response.

Keywords

Schedule 13D, Amendment, Beneficial Ownership, CRYO CELL INTERNATIONAL INC, Camac Partners, Camac Capital, Camac Fund, Eric Shahinian, Investment, Securities, Common Stock, Shareholder Activism, Corporate Governance